Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

600332

Classement en actions #3634
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GBPHCL), along... Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GBPHCL), along with its various subsidiaries, operates as a comprehensive pharmaceutical enterprise. It is actively engaged in the research, development, production, and distribution of a wide array of products, including traditional Chinese patent medicines, Western pharmaceuticals, chemical raw materials, natural and biological medications, and chemical raw material intermediates. Its operations span both the People's Republic of China and international markets. The company structures its extensive operations into four primary segments: Great Southern TCM, Great Commerce, Great Health, and a miscellaneous 'Others' category. Beyond its core pharmaceutical manufacturing, GBPHCL's activities extend to the wholesale, retail, import, and export of both Western and traditional Chinese medicines, as well as medical apparatus and instruments. Furthermore, its diverse product portfolio encompasses the research, development, production, and sale of consumer health items such as beverages, various food products (including pre-packaged items and dairy), and a broad range of pharmaceutical formulations like tablets, capsules, lozenges, injections, and even traditional specialties like tortoise herb jelly. The group also strategically invests in the broader health industry, focusing on areas like medical care, health management, health preservation, and elderly care. Complementing these activities, it offers commercial and advertising services. As of December 31, 2021, GBPHCL maintained a substantial retail presence, operating 154 chain pharmacy outlets. This network comprised 22 Cai Zhi Lin pharmacies, 36 Jian Min pharmacies, 51 GPC Prescription Pharmacy locations, and 23 Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd. outlets, alongside an additional 22 general retail stores. Tracing its origins back to its incorporation in 1997, the company was initially known as Guangzhou Pharmaceutical Company Limited. It adopted its current name, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, in August 2013. The company is headquartered in Guangzhou, China.
Prix de l'action
$2.95
Capitalisation boursière
$4.61B
Changement (1 jour)
-0.20%
Changement (1 an)
-18.24%
Pays
CN
Échange Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (600332)

Catégorie

Healthcare
Ratio P/E pour Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (600332)
Ratio P/E au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, le ratio P/E actuel (TTM) est de 0. À la fin de l’année 2026, le P/E de l’entreprise était de 0.
Historique du ratio P/E pour Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited de 2026 à 2026
Ratio P/E à la fin de chaque année
Année Ratio P/E Changez
Pas assez de données pour les dates fournies.
Ratio P/E pour des entreprises similaires ou concurrentes
Comment lire un P/E ratio ?

Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.

Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.

Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.